Akoya Biosciences announced an achievement – publication of the 1,000th peer-reviewed article citing use of the company’s technology, the largest publication volume in the industry. Approximately 80% of these articles have been published in the last 2.5 years, reflecting the exponential growth in adoption of Akoya’s solutions. While the majority of publications have focused on oncology, other areas of research include inflammatory disease, neuroscience, and infectious diseases. “Our team is thrilled to celebrate the achievement of 1,000 publications,” said Brian McKelligon, CEO of Akoya Biosciences. “We are humbled by the trust the scientific community has placed in our technology, and we are excited to continue advancing discovery in spatial biology.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AKYA:
- Akoya Reports Record Revenue in the Second Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
- Akoya Biosciences Announces Milestone of 1,000 Peer-Reviewed Publications Citing Use of its Spatial Biology Technologies
- AKYA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Akoya to Participate at Three Upcoming Investor Conferences
- Akoya to Report Second Quarter 2023 Financial Results on August 7th, 2023
